Development and Validation of a Stability-Indicating HPLC Method for the Quantitative Estimation of Resmetirom
Keywords:
Resmetirom, Sensitivity, Selectivity, Reverse phase HPLC and ValidationAbstract
The present paper describes the development and validation of a simple, precise, and stability-indicating reverse-phase high-performance liquid chromatographic (RP-HPLC) method for the quantitative estimation of Resmetirom in bulk and pharmaceutical formulations. Chromatographic separation was achieved using a C18 column with a mobile phase consisting of acetonitrile and phosphate buffer in an optimized ratio under isocratic conditions. The flow rate, detection wavelength, and injection volume were systematically optimized to provide sharp, symmetrical peaks with adequate resolution. Resmetirom exhibited a retention time that ensured effective separation from degradation products and excipients. The method was validated in accordance with ICH Q2(R1) guidelines for specificity, linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ). Linearity was observed over a suitable concentration range with a correlation coefficient (R²) greater than 0.999, demonstrating excellent proportionality between peak area and analyte concentration.
References
ICH Q1A(R2). Stability Testing of New Drug Substances and Products. International Council for Harmonisation, Geneva, Switzerland.
ICH Q2(R1). Validation of Analytical Procedures: Text and Methodology. International Council for Harmonisation.
Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography, 3rd ed.; Wiley: New York, 2010.
Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability-indicating studies of drugs—A review. J Pharm Anal. 2014;4(3):159–165.
Harrison SA et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicenter, randomized, double-blind, placebo- controlled trial. J Clin Endocrinol Metab. 2023;108(7):1602–1614.
Bakshi M, Singh S. Development of validated stability-indicating assay methods—critical review. J Pharm Biomed Anal. 2002;28(6):1011–1040.
